Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

NCT04588077 is registered in ClinicalTrials.gov with Mercy Medical Center as lead sponsor.

NCT NCT04588077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
Lead sponsor
Mercy Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
September 14, 2020
Completion date
December 1, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic liver disease, cirrhosis, liver, hepatitis b